#027 Danny Motyka: psychedelics as a prophylactic
Psychedelic Diaries episode summary:
We talk with Danny Motyka — CEO of Psygen — about LSD vs magic mushrooms, ego death on ketamine, and how psychedelic brains react to trauma.
— NUGGET AND A NOODLE: Health Canada allows physicians to request access to restricted psychedelics on behalf of patients; how to replace the myth that psychedelics are dangerous? (0:25)
— How AI can help humans solve complex problems, if we learn to trust it (2:26)
— Danny's surprise at the lack of manufacturers in the psychedelics industry (3:57)
— Danny shares how his journey with psychedelics started as a depressed teenager (5:58)
— Ego death experiences, attempted suicide and how Danny credits psilocybin with saving his life (9:00)
— LSD versus magic mushrooms and Danny's largest dose (11:27)
— How PsyGen's roadmap relates to adult prophylactic use (13:03)
— What Danny considers intentional use, and what gets him excited as a CEO (16:23)
SOUL SEARCH: Who's the one person who has had the greatest impact on your career?... (19:00)
Danny Motyka brings a unique perspective to the future of psychedelics, with a decades-long devotion to psychedelic activism and study, firsthand understanding of the life-changing effects of plant medicine, and his work as CEO of Psygen Labs. Danny Motyka has long advocated for the use of psychedelic medicines. Personal experiences with psilocybin and LSD aided him in understanding and managing serious depression, leading him to pursue a career in psychedelic medicinal chemistry. He began his career at Aurora Cannabis after finishing with an Honours Degree in Chemistry from the University of Victoria. He is now the CEO of Psygen Labs, a pharmaceutical-grade psychedelic chemical product manufacturer for clinical research and medicinal uses.
Find Danny here:
Watch the episode now: